Showing 621 - 640 results of 103,443 for search '(( 5 ((((026 decrease) OR (a decrease))) OR (nn decrease)) ) OR ( 2 de decrease ))', query time: 1.45s Refine Results
  1. 621

    Pre-treatment with GnRHa or <i>ulipristal acetate</i> prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis by Inge de Milliano (4515127)

    Published 2017
    “…Pre-treatment with GnRHa before laparoscopic myomectomies also shows a reduction in intra-operative blood loss by 23.03ml (95% CI -40.79 to -5.27) and in the frequency of blood transfusions (OR 0.17, 95% CI 0.05 to 0.55) compared to no pre-treatment.…”
  2. 622
  3. 623
  4. 624
  5. 625
  6. 626
  7. 627
  8. 628
  9. 629
  10. 630
  11. 631
  12. 632
  13. 633
  14. 634
  15. 635
  16. 636
  17. 637
  18. 638

    Table_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  19. 639

    Table_3_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  20. 640

    Table_4_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”